Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone dosing timing in adults with type 2 diabetes
ACTRN12614000204640Phase 4Terminated
- Sponsor
- Baker Heart and Diabetes Institute
- Start
- Jul 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of prednisolone in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Baker Heart and Diabetes Institute. Primary endpoint: Time per day with interstitial glucose at or above 10.0 mmol/L. Started Jul 2014; status: terminated.
02
Drugs
prednisolone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12614000204640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000204640.